Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druzhestven N IzsledovatelskifiledCriticalDruzhestven N Izsledovatelski
Priority to BG9452291ApriorityCriticalpatent/BG51386A1/en
Publication of BG51386A1publicationCriticalpatent/BG51386A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
The antitumour medication is applicable in the medical practice. It is highly efficient at low doses and tolerant by the human body. When taken, it exhibits no lateral or immunosuppressive effects. No teratogenic, carcinogenic, and allergic properties are observed. It contains 1-(4-amino-3,5-dichlorophenyl)-2-tetrabutyl aminoethanol chloride (clenbuterol).